Publicaciones en colaboración con investigadores/as de Princess Margaret Cancer Centre (10)

2022

  1. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

    Clinical Cancer Research, Vol. 28, Núm. 16, pp. 3452-3463

2021

  1. First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

    Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676

2020

  1. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment

    Investigational New Drugs, Vol. 38, Núm. 6, pp. 1774-1783

2019

  1. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 178, Núm. 1, pp. 121-133

  2. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

    ESMO Open, Vol. 4, Núm. 4

  3. Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

    Gynecologic Oncology, Vol. 152, Núm. 1, pp. 53-60

2018

  1. Integration of oncology and palliative care

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii553

  2. Integration of oncology and palliative care: a Lancet Oncology Commission

    The Lancet Oncology, Vol. 19, Núm. 11, pp. e588-e653

  3. Phase II study of Taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor–positive advanced breast cancer

    Clinical Cancer Research, Vol. 24, Núm. 18, pp. 4380-4387

2015

  1. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial

    The Lancet Oncology, Vol. 16, Núm. 8, pp. 928-936